Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Ramesh A. Shivdasani, Yotam Drier et al.|Nature Medicine|2019Cited by 185
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Clinical Cancer Research|2023Cited by 46
Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Ramesh A. Shivdasani, Yotam Drier et al.|Nature Medicine|2019Cited by 5
Data from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Unknown|2023Cited by 0
Supplementary Table S10 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Matthew Meyerson et al.|Unknown|2023Cited by 0